Economy

Boston Scientific Corporation (BSX) Stake Increased by Janus Henderson Group PLC

Tributary Capital Management Llc decreased Boston Scientific Corp Com (BSX) stake by 68.95% reported in 2017Q2 SEC filing. The firm owned 292,474 shares of the medical equipment provider's stock after purchasing an additional 6,495 shares during the quarter. Finally, Peddock Capital Advisors LLC bought a new position in Boston Scientific Corporation during the 2nd quarter valued at $201,000. It increased, as 41 investors sold BSX shares while 173 reduced holdings. The company had a trading volume of 3,383,917 shares. Guardian Life Insurance Co. of America now owns 5,266 shares of the medical equipment provider's stock worth $131,000 after buying an additional 49 shares during the period. Comerica Securities Inc. increased its holdings in shares of Boston Scientific Corporation by 0.9% during the 2nd quarter. Toronto Dominion Bank now owns 463,826 shares of the medical equipment provider's stock valued at $12,854,000 after purchasing an additional 95,902 shares during the period. Quadrant Capital Group LLC boosted its position in Boston Scientific by 10.3% in the first quarter. Cleararc Capital Inc. now owns 33,322 shares of the medical equipment provider's stock worth $829,000 after purchasing an additional 251 shares during the period. They now have a $34.00 price target on the medical equipment provider's stock. The institutional investor held 579,918 shares of the medical and dental instruments company at the end of 2017Q2, valued at $16.08M, down from 715,558 at the end of the previous reported quarter. Verity Asset holds 0.18% in Boston Scientific Corporation (NYSE:BSX) or 8,424 shares. Through this figure traders can analyze that BSX show whether or not a stock now most active and standing in buying side or sell side. The company maintains price to book ratio of 0.00 vs.an industry average at 0.56. The firm has a 50-day moving average of $28.71 and a 200-day moving average of $27.19.

Boston Scientific Corporation (NYSE:BSX), stock is trading $29.54 above the 52-week high and has displayed a high EPS growth of -2.80% in last 5 years.

Analysts await Boston Scientific Corporation (NYSE:BSX) to report earnings on October, 25. The medical equipment provider reported $0.29 EPS for the quarter, missing the Zacks' consensus estimate of $0.30 by $0.01. Boston Scientific had a return on equity of 23.70% and a net margin of 4.14%. The company had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.21 billion. Its sales stood at 44.90% a year on average in the period of last five years. The firm's revenue was up 6.2% compared to the same quarter past year. Boston Scientific Corporation had 63 analyst reports since July 27, 2015 according to SRatingsIntel. (MGNX) price hitting a mean target of $30 a share, meaning the stock still has potential that could lift the price another 71.23% Also, the recent close suggests the stock is underpriced by 151.14% compared to the most bullish target. Following the completion of the sale, the executive vice president now directly owns 174,681 shares in the company, valued at approximately $5,107,672.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP John Bradley Sorenson sold 2,100 shares of the firm's stock in a transaction on Monday, July 31st. The stock was sold at an average price of $29.12, for a total transaction of $10,108,629.44. The disclosure for this sale can be found here.

BTIG Research maintained the shares of BSX in report on Sunday, September 6 with "Buy" rating. Jefferies Group LLC restated a "hold" rating and set a $26.00 price target on shares of Boston Scientific in a report on Friday, February 3rd. The stock of Boston Scientific Corporation (NYSE:BSX) has "Buy" rating given on Wednesday, June 28 by Barclays Capital. That's a potential 4.76 increase relative to where Boston Scientific Corporation (NYSE:BSX) has been trading recently. Zacks Investment Research cut Boston Scientific from a "hold" rating to a "sell" rating in a report on Wednesday, April 5th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. The company now has a consensus rating of "Buy" and a consensus target price of $30.13.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Equities Focus and is the property of of Equities Focus. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of USA & worldwide copyright & trademark legislation. The legal version of this piece can be viewed at https://www.truebluetribune.com/2017/10/15/boston-scientific-corporations-bsx-buy-rating-reiterated-at-suntrust-banks-inc.html.

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX?



Like this

loading...
loading...

Latest


15 October 2017
China's runaway space station is headed for a crash landing into Earth
Tiangong-1, which means heavenly palace in English, comprises of single-module with only one docking port for Shenzhou spacecraft. It was used for both manned and unmanned missions and visited by China's first female astronaut, Liu Yang, in 2012.

15 October 2017
Montgomery scores 3 TDs as Cyclones blank Jayhawks
Moos fumbled a snap, giving Iowa State the ball at the Jayhawks' 27-yard line early in the third quarter. An very bad day for KU's special teams further derailed any hope for an upset road win.

15 October 2017
Golden Knights put Fleury, Marchessault on injured reserve
Fleury, 32, won three Stanley Cups with the Penguins before being selected by the Golden Knights in the expansion draft. It is also worth noting that Fleury is now dealing with a concussion and will miss at least the next week of action.

15 October 2017
Next Weeks Broker Price Targets For NXP Semiconductors NV (NASDAQ:NXPI)
Macquarie Research maintained it with "Outperform" rating and $280 target in Wednesday, September 28 report. Manufacturers Life Insurance The has invested 0.02% in Westinghouse Air Brake Technologies Corp (NYSE:WAB).

15 October 2017
PSA says to cut about 400 jobs at Vauxhall's Ellesmere Port
The move aimed to secure GM's exit from the United Kingdom and Europe while transforming PSA into Europe's second-largest auto maker.

15 October 2017
Energy drink consumption leaves man with a hole in his head: claim
She helps him with personal hygiene and with his occupational, speech, and physical therapy, all while taking care of their child. As Yahoo ! shares, a woman named Brianna shares that her husband, Austin, had a brain hemorrhage that left a hole in his skull.

15 October 2017
MS Dhoni and Ziva share 'besan ka laddoo'
The Indian cricket team members have got a short break following the conclusion of their T20I series against Australia. The Indian skipper also posted a video of the meet-up on his Instagram. "My reunion with Ziva".

15 October 2017
UK, Germany reiterate commitment to Iran nuclear deal
AIPAC is one of the most influential lobbying groups in America, helping advance Israel-American policy decisions in Congress. The deal was also created to halt Iranian nuclear proliferation for 10 to 15 years.

15 October 2017
SVB Financial Group's (SIVB) Overweight Rating Reiterated at Morgan Stanley
New Amsterdam Partners Llc increased Green Plains Inc (NASDAQ:GPRE) stake by 36,544 shares to 240,385 valued at $4.94M in 2017Q2. Descheneaux Michael sold $1.29M worth of stock or 7,000 shares. 4,600 shares were sold by BILNEY JODY L , worth $1.06M.

15 October 2017
Larry Flynt Offered USD 10 Million for Information Discrediting Trump
The man declined to give his name but said he was not Flynt. There is a number at the bottom and an email address. Larry Flynt's full-page ad in The Washington Post .